Cover Image
Market Research Report

Global Tyrosine Kinase Inhibitors Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 763595
Published Content info 115 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Tyrosine Kinase Inhibitors Market 2019-2023
Published: December 17, 2018 Content info: 115 Pages
Description

About this market

Strategic alliances to trend in the market. The growing prevalence of various diseases increases the demand for innovative therapeutics. TKI therapeutics are one of the most reliable therapeutic options for the treatment of cancer and age-related diseases such as RVO. Technavio' s analysts have predicted that the tyrosine kinase inhibitors market will register a CAGR of more than 8% by 2023.

Market Overview

Recent approvals of TKIs

Many TKI therapeutic candidates are gaining approval due to their high safety profile and efficacy. The therapeutics that are in last stage of development are expected to get marketing approval during forecast period.

Side effects of TKIs

Despite highly efficacious, TKIs are associated with a spectrum of side effects such as fatigue, muscle cramps, nausea, vomiting, and diarrhea.

For the detailed list of factors that will drive and challenge the growth of the tyrosine kinase inhibitors market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer the competitive environment is quite intense. Factors such as the rising strategic alliances and the recent approvals of TKIs, will provide considerable growth opportunities to tyrosine kinase inhibitors manufactures. Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, Novartis, and Pfizer are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR30518

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • The threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • RTKIs - Market size and forecast 2018-2023
  • nRTKIs - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Novartis
  • Pfizer

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ billions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: RTKIs - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 21: RTKIs - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: nRTKIs - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 23: nRTKIs - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: Americas - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in Americas
  • Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 32: Example of patient-assistance program for cancer treatment
  • Exhibit 33: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in EMEA
  • Exhibit 35: APAC - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in APAC
  • Exhibit 38: Key leading countries
  • Exhibit 39: Market opportunity
  • Exhibit 40: Decision framework
  • Exhibit 41: Reported top 5 new cases of cancer types in US in 2015
  • Exhibit 01: Treatment costs of TKIs
  • Exhibit 02: Side effects of TKIs
  • Exhibit 03: Impact of drivers and challenges
  • Exhibit 07: Vendor landscape
  • Exhibit 08: Landscape disruption
  • Exhibit 09: Vendors covered
  • Exhibit 10: Vendor classification
  • Exhibit 11: Market positioning of vendors
  • Exhibit 12: Bristol-Myers Squibb - Vendor overview
  • Exhibit 13: Bristol-Myers Squibb - Business segments
  • Exhibit 14: Bristol-Myers Squibb - Organizational developments
  • Exhibit 15: Bristol-Myers Squibb - Geographic focus
  • Exhibit 16: Bristol-Myers Squibb - Key offerings
  • Exhibit 17: Bristol-Myers Squibb - Key customers
  • Exhibit 18: F. Hoffmann-La Roche - Vendor overview
  • Exhibit 19: F. Hoffmann-La Roche - Business segments
  • Exhibit 20: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 21: F. Hoffmann-La Roche - Geographic focus
  • Exhibit 22: F. Hoffmann-La Roche - Segment focus
  • Exhibit 23: F. Hoffmann-La Roche - Key offerings
  • Exhibit 24: F. Hoffmann-La Roche - Key customers
  • Exhibit 25: Johnson & Johnson - Vendor overview
  • Exhibit 26: Johnson & Johnson - Business segments
  • Exhibit 27: Johnson & Johnson - Organizational developments
  • Exhibit 28: Johnson & Johnson - Geographic focus
  • Exhibit 29: Johnson & Johnson - Segment focus
  • Exhibit 30: Johnson & Johnson - Key offerings
  • Exhibit 31: Johnson & Johnson - Key customers
  • Exhibit 32: Novartis - Vendor overview
  • Exhibit 33: Novartis - Business segments
  • Exhibit 34: Novartis - Organizational developments
  • Exhibit 35: Novartis - Geographic focus
  • Exhibit 36: Novartis - Segment focus
  • Exhibit 37: Novartis - Key offerings
  • Exhibit 38: Novartis - Key customers
  • Exhibit 39: Pfizer - Vendor overview
  • Exhibit 40: Pfizer - Business segments
  • Exhibit 41: Pfizer - Organizational developments
  • Exhibit 42: Pfizer - Geographic focus
  • Exhibit 43: Pfizer - Segment focus
  • Exhibit 44: Pfizer - Key offerings
  • Exhibit 45: Pfizer - Key customers
  • Exhibit 46: Validation techniques employed for market sizing
  • Exhibit 47: List of abbreviations
Back to Top